发布求助
文献互助 智能选刊 最新文献

American journal of therapeutics最新文献

筛选
英文 中文
Abrocitinib for Erythema Multiforme-like Drug Eruptions. 阿布替尼治疗多形性红斑样药疹。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1097/MJT.0000000000002153
Xiang-Yu Chen, Xin-Yu Wei, Bing-Jun Shi
{"title":"Abrocitinib for Erythema Multiforme-like Drug Eruptions.","authors":"Xiang-Yu Chen, Xin-Yu Wei, Bing-Jun Shi","doi":"10.1097/MJT.0000000000002153","DOIUrl":"10.1097/MJT.0000000000002153","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e354-e358"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofacitinib for Pigmented Purpuric Dermatoses: Subtype-Specific Therapeutic Responses and Clinical Implications. 托法替尼治疗色素性紫癜性皮肤病：亚型特异性治疗反应和临床意义。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1097/MJT.0000000000002058
Yu-Ting Gan, Shi Yan, Yi Liu, Feng-Lin Chen
{"title":"Tofacitinib for Pigmented Purpuric Dermatoses: Subtype-Specific Therapeutic Responses and Clinical Implications.","authors":"Yu-Ting Gan, Shi Yan, Yi Liu, Feng-Lin Chen","doi":"10.1097/MJT.0000000000002058","DOIUrl":"10.1097/MJT.0000000000002058","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e358-e359"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline. 致幻剂治疗：初级保健临床医生的入门-美斯卡灵。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-17 DOI: 10.1097/MJT.0000000000002160
Burton J Tabaac, Kenneth Shinozuka, Mahdi Fadel, Greg Jones, Jared Worchel, Owen S Muir
{"title":"Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline.","authors":"Burton J Tabaac, Kenneth Shinozuka, Mahdi Fadel, Greg Jones, Jared Worchel, Owen S Muir","doi":"10.1097/MJT.0000000000002160","DOIUrl":"10.1097/MJT.0000000000002160","url":null,"abstract":"<p><strong>Background: </strong>Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is renewed scientific interest in mescaline because of the potential psychiatric benefits of psychedelic-assisted therapy. Mescaline primarily exerts its psychoactive effects through serotonin-2A (5-HT 2A ) receptor agonism.</p><p><strong>Areas of uncertainty: </strong>There is a lack of controlled clinical trials evaluating mescaline in patient populations, and most modern safety data are derived from healthy volunteers. Consequently, its safety in individuals with cardiovascular, metabolic, or psychiatric comorbidities remains unclear. Additional uncertainty exists regarding its psychological risks, long duration of action, and long-term safety in therapeutic settings.</p><p><strong>Therapeutic advances: </strong>Randomized, placebo-controlled studies in healthy participants demonstrate that mescaline produces dose-dependent subjective effects with moderate, transient autonomic stimulation and no serious medical complications under controlled conditions. Adverse effects are generally self-limited, and pooled safety analyses and observational data support an overall favorable safety profile in screened human populations.</p><p><strong>Conclusion: </strong>Mescaline shows preliminary safety in healthy humans but remains understudied in clinical populations. Controlled clinical trials are needed to establish its safety and therapeutic potential.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e318-e323"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Pressure Targets in Thoracic Aortic Disease: A Practical Comparison of ACC/AHA Guidance and Post-2024 European Guidelines. 胸主动脉疾病的血压目标：ACC/AHA指南和2024年后欧洲指南的实际比较
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1097/MJT.0000000000002158
Georgios Tournas Androulakis, Argyro Papadopoulou
{"title":"Blood Pressure Targets in Thoracic Aortic Disease: A Practical Comparison of ACC/AHA Guidance and Post-2024 European Guidelines.","authors":"Georgios Tournas Androulakis, Argyro Papadopoulou","doi":"10.1097/MJT.0000000000002158","DOIUrl":"10.1097/MJT.0000000000002158","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e333-e335"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Comment on: Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial," for Potential Publication in the American Journal of Therapeutics. 《评论：法莫替丁加或不加法莫替丁治疗澳大利亚COVID-19感染患者的多模式治疗（伊维菌素、多西环素、维生素C、维生素D和锌）的安全性和耐受性：一项试点队列试验》，即将在《美国治疗学杂志》上发表。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-05 DOI: 10.1097/MJT.0000000000002135
Nawazish Ali, Muneeba Attique, Musawar Khan, Aqib Ali, Atif Hussain
{"title":"\"Comment on: Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial,\" for Potential Publication in the American Journal of Therapeutics.","authors":"Nawazish Ali, Muneeba Attique, Musawar Khan, Aqib Ali, Atif Hussain","doi":"10.1097/MJT.0000000000002135","DOIUrl":"10.1097/MJT.0000000000002135","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e361-e362"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148161479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing Clinical Effects of 7-Hydroxymitragynine at a US Poison Control Center. 在美国中毒控制中心描述7-羟米特拉吉宁的临床效果。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-04-29 DOI: 10.1097/MJT.0000000000002134
Taylor N Wahrenbrock, Madison Bompard, John W Downs
{"title":"Characterizing Clinical Effects of 7-Hydroxymitragynine at a US Poison Control Center.","authors":"Taylor N Wahrenbrock, Madison Bompard, John W Downs","doi":"10.1097/MJT.0000000000002134","DOIUrl":"10.1097/MJT.0000000000002134","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e339-e341"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Levodopa Withdrawal Presenting as Fever in a Patient Receiving Concomitant Enteral Nutrition: A Case Report and Literature Review. 左旋多巴戒断患者同时接受肠内营养时表现为发热：1例报告及文献回顾。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1097/MJT.0000000000002162
Yu-Shuang Qiu, Di Zhao, Pei-Pei Meng, Dong-Jie Li, Yi-Bo Fei, Bo Yang, Fu-Ming Shen
{"title":"Levodopa Withdrawal Presenting as Fever in a Patient Receiving Concomitant Enteral Nutrition: A Case Report and Literature Review.","authors":"Yu-Shuang Qiu, Di Zhao, Pei-Pei Meng, Dong-Jie Li, Yi-Bo Fei, Bo Yang, Fu-Ming Shen","doi":"10.1097/MJT.0000000000002162","DOIUrl":"10.1097/MJT.0000000000002162","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e335-e339"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148256980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Upadacitinib as a Successful Sequential Therapy After Abrocitinib Failure in a Patient With Refractory Darier Disease. 在阿布替尼治疗失败后，Upadacitinib作为一种成功的序贯疗法治疗难治性肾癌患者。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1097/MJT.0000000000002091
Yu-Ting Gan, Shi Yan, Wei-Na Xie, Yi Liu, Feng-Lin Chen
{"title":"Upadacitinib as a Successful Sequential Therapy After Abrocitinib Failure in a Patient With Refractory Darier Disease.","authors":"Yu-Ting Gan, Shi Yan, Wei-Na Xie, Yi Liu, Feng-Lin Chen","doi":"10.1097/MJT.0000000000002091","DOIUrl":"10.1097/MJT.0000000000002091","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e352-e354"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148256978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-Dependent Escitalopram-Induced Anejaculation and Anorgasmia: Rapid Reversal After Discontinuation and Bupropion Therapy. 剂量依赖性艾司西酞普兰诱导的射精和性障碍：停药和安非他酮治疗后的快速逆转。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-22 DOI: 10.1097/MJT.0000000000002173
Ravindra N Munoli, Shubham Gupta, Samir K Praharaj
{"title":"Dose-Dependent Escitalopram-Induced Anejaculation and Anorgasmia: Rapid Reversal After Discontinuation and Bupropion Therapy.","authors":"Ravindra N Munoli, Shubham Gupta, Samir K Praharaj","doi":"10.1097/MJT.0000000000002173","DOIUrl":"10.1097/MJT.0000000000002173","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e350-e352"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety. Deucravacitinib治疗广泛性脓疱性银屑病和合并症多发性肌炎：双重疗效和良好的安全性。
IF 3.5 4区 医学
American journal of therapeutics Pub Date : 2026-06-29 DOI: 10.1097/MJT.0000000000002176
Yuan-Fang Wan, Xiao-Rong Deng, Ya Zhao, Feng-Lin Chen
{"title":"Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.","authors":"Yuan-Fang Wan, Xiao-Rong Deng, Ya Zhao, Feng-Lin Chen","doi":"10.1097/MJT.0000000000002176","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002176","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书